Hims & Hers (HIMS) shares are reeling after Novo Nordisk (NVO) severs its weight-loss drug relationship with the telehealth company. NVO claims HIMS was marketing knock-off weight loss drugs using "deceptive promotion" tactics. George Tsilis weighs in on why HIMS is down 30% on the news, and how it impacts the company's personalization care business segment. He points to possible red flags with ingredients coming from China and a lack of quality control over the use of weight-loss medication.
Next Gen Investing
23 Jun 2025
SHARE